Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

被引：0

作者：

Bobin, Arthur ^{[1
]}

Hulin, Cyrille ^{[2
]}

Lambert, Jerome ^{[3
]}

Perrot, Aurore ^{[4
]}

Manier, Salomon ^{[5
]}

Montes, Lydia ^{[6
]}

Jaccard, Arnaud ^{[7
]}

Karlin, Lionel ^{[8
]}

Godmer, Pascal ^{[9
]}

Caillot, Denis ^{[10
,11
]}

Chalopin, Thomas ^{[12
]}

Roul, Christophe ^{[13
]}

Mariette, Clara ^{[14
]}

Rigaudeau, Sophie ^{[15
]}

Delaunay, Jacques ^{[16
]}

Dingremont, Claire ^{[17
]}

Santagostino, Alberto ^{[18
]}

Dib, Mamoun ^{[19
]}

Macro, Margaret ^{[20
]}

Tiab, Mourad ^{[21
]}

Laribi, Kamel ^{[22
]}

Petit, Emmanuelle Bourgeois ^{[23
]}

Calmettes, Claire ^{[24
]}

Piocelle, Frederique Orsini ^{[25
]}

Bareau, Benoit ^{[26
]}

Tabrizi, Reza ^{[27
]}

Vincent, Laure ^{[28
]}

Mohty, Mohamad ^{[29
]}

Touzeau, Cyrille ^{[30
]}

Corre, Jill ^{[31
]}

Moreau, Philippe ^{[32
]}

Facon, Thierry ^{[33
]}

Loiseau, Herve Avet ^{[34
]}

Leleu, Xavier ^{[35
,36
]}

机构：

[1] CHU Poitiers, Poitiers, France

[2] Ctr Hosp Univ Bordeaux, Pessac, France

[3] Univ Paris Cite, St Louis Univ Hosp, AP HP, Biostat & Med Informat Dept, Paris, France

[4] Inst Univ Canc Toulouse Oncopole, Serv Hematol, Toulouse, France

[5] Ctr Hosp Univ Hop Huriez, Lille, France

[6] Ctr Hosp Univ Amiens Picardie, Serv Hematol Clin, Amiens, France

[7] CHU Limoges, Hematol Clin, Hop Dupuytren, Limoges 1, France

[8] Hosp Civils Lyon, Hop Lyon Sud, Pierre Benite, France

[9] CH Vannes, Vannes, France

[10] Univ Burgundy & France Comte, Univ Hosp INSERM UMR1231, Dijon, France

[11] Univ Burgundy & France Comte, SAPHIIR UMR 1231, Dijon, France

[12] Ctr Hosp Univ Tours, Tours, France

[13] CH La Rochelle, La Rochelle, France

[14] CHU Grenoble, Grenoble, France

[15] CH Versailles, Le Chesnay Rocquencourt, France

[16] Ctr Hosp Univ Nantes, Nantes, France

[17] Ch Tarbes, Tarbes, France

[18] CH Troyes, Troyes, France

[19] CHU Angers, Angers, France

[20] Hop Cote De Nacre, Caen, France

[21] Ctr Hosp Dept, La Roche Sur Yon 9, France

[22] Le Mans Hosp, Hematol Dept, Le Mans, France

[23] CHU Lille, Lille, France

[24] CH Perigueux, Perigueux, France

[25] CH Metz, Metz Tessy, France

[26] Cabinet Med, Rennes, France

[27] CH Mont de Marsan, Mont De Marsan, France

[28] Montpellier Univ, Hosp Ctr, Dept Clin Hematol, Montpellier, France

[29] Hop St Antoine, Paris, France

[30] Ctr Hosp Univ Nantes, Nantes, France

[31] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[32] Univ Hosp Hotel Dieu, Nantes, France

[33] Lille Univ Hosp, Dept Haematol, Lille, France

[34] Univ Hosp Toulouse, IUCT Oncopole, Unite Genom Myelome, Toulouse, France

[35] Serv Hematol & Therapie Cellulaire, Poitiers, France

[36] Univ Poitiers Hosp, INSERM CIC 1042, Poitiers, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185699

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[41] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Pei, H.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 317
[42] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
Moreau, P.
Facon, T.
Usmani, S. Z.
Bahlis, N.
Raje, N.
Plesner, T.
Orlowski, R. Z.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Weisel, K.
Tiab, M.
Macro, M.
Frenzel, L.
Leleu, X.
Wang, G.
Krevvata, M.
Carson, R.
Borgsten, F.
Kumar, S. K.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
[43] Isatuximab Rescue for Inadequate Response to Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: Interim Analysis of the Phase II Iril Study of the Australian Myeloma Research Consortium (AMaRC 18-02)
Ninkovic, Slavisa
Murphy, Nicholas E.
Sidiqi, Hasib
Wallington-Beddoe, Craig Thomas
Puliyayil, Anish
Yannakou, Costas K.
Janowski, Wojt
Yuen, Flora
Spencer, Andrew
Quach, Hang
BLOOD, 2021, 138
[44] Bortezomib, lenalidomide, and dexamethasone (VRd) daratumumab (DARA) in patients (pts) with transplant -eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase Ill study (PERSEUS).
Sonneveld, Pieter
Broijl, Annemiek
Gay, Francesca
Boccadoro, Mario
Einsele, Hermann
Blade, Joan
Dimopoulos, Meletios A.
Delforge, Michel
Spencer, Andrew
Hajek, Roman
Schjesvold, Fredrik
Lonergan, Sarah
Smith, Elena
Carson, Robin L.
Crist, Wendy
Garvin, Wendy S.
Vermeulen, Jessica
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[45] MagnetisMM-7: an open-label, multicenter, randomized phase 3 study of elranatamab versus lenalidomide in post-transplant patients with newly diagnosed multiple myeloma
Kortuem, M.
Manteca, Mateos M. V.
Grosicki, S.
Kim, K.
Negre, E.
Vandendries, E.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 182 - 182
[46] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
Usmani, Saad Z.
Kumar, Shaji
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Perrot, Aurore
Venner, Chris P.
Weisel, Katja
Mace, Joseph R.
Raje, Noopur S.
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Van Rampelbergh, Rian
Tromp, Brenda
Delioukina, Maria
Facon, Thierry
BLOOD, 2021, 138
[47] Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Zhou, Huixing
Chang, Long
Jia, Jing
Ma, Jie
Xue, Hua
Li, Hao
Huang, Wenrong
Zhou, Hebing
Sun, Jingnan
Su, Liping
Ma, Yanping
Huang Hongming
Jing, Hongmei
Li, Zhenling
Ma, Guangyu
Su, Guohong
Zhou, Jihao
Chen, Biyun
Bao, Li
Zhang, Zhihua
BLOOD, 2023, 142
[48] An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Dimopoulos, Meletios
Grosicki, Sebastian
Jedrzejczak, Wieslaw
Nahi, Hareth
Gruber, Astrid
Hansson, Markus
Byrne, Catriona
Labotka, Richard
Teng, Zhaoyang
Yang, Huyuan
Grzasko, Norbert
Kumar, Shaji
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S333 - S334
[49] Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
Dimopoulos, Meletios A.
Cheung, Matthew C.
Roussel, Murielle
Liu, Ting
Gamberi, Barbara
Kolb, Brigitte
Derigs, H. Guenter
Eom, HyeonSeok
Belhadj, Karim
Lenain, Pascal
Van der Jagt, Richard
Rigaudeau, Sophie
Dib, Mamoun
Hall, Rachel
Jardel, Henry
Jaccard, Arnaud
Tosikyan, Axel
Karlin, Lionel
Bensinger, William
Schots, Rik
Leupin, Nicolas
Chen, Guang
Marek, Jennifer
Ervin-Haynes, Annette
Facon, Thierry
HAEMATOLOGICA, 2016, 101 (03) : 363 - 370
[50] Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Orlowski, Robert
Facon, Thierry
Kumar, Shaji
Plesner, Torben
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher
Weisel, Katja
Mace, Joseph
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Ahmadi, Tahamtan
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa
Tromp, Brenda
Delioukina, Maria
Vermeulen, Jessica
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S425

← 1 2 3 4 5 →